Toripalimab
Monoclonal antibody
Evidence outlook
Approved: Nasopharyngeal Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 3 · under NMPA reviewCholangiocarcinoma · Phase 3
Also approved (2)
- First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
- Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Company guidance: data expected 2H 2026 (NCT07796126; Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.” Source ↗
Company guidance: data expected 2H 2026 (Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b/2a study evaluating the tagmokitug and toripalimab combination in fourth-line and beyond colorectal cancer with no liver metastasis, is fully enrolled, with initial data expected in 2H 2026.” Source ↗
Company guidance: topline data expected 1H 2027 (Coherus BioSciences, Inc., 9 Nov 2026). “● Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02915432 NCT02915432 · Nasopharyngeal Carcinoma Registry: NCT02915432 | 1/2 | Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Up to 1.5 approximately years) 2020-02-19 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT03581786 NCT03581786 · Nasopharyngeal Carcinoma JUPITER-02 was a randomized, double-blind, placebo-controlled Phase 3 in 289 patients with recurrent or metastatic nasopharyngeal carcinoma. Its primary endpoint, independently reviewed progression-free survival, is a clinical outcome and was met (HR 0.52). Figures are from the FDA label; the sources read give no power calculation, so the grade is moderate. Registry: NCT03581786 | 3 | IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 (up to 2 years) 2020-05-30 | Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (56)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (342)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (70)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (74)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Appears in other studies (14)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Cholangiocarcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Toripalimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Futibatinib (Lytgobi) | Approved | Small molecule | FGFR (FGFR1/2/3/4) | Weak signal | No reviewed efficacy summary in this indication | |
| Lirafugratinib (Lyrfigtu) | Approved | Small molecule | FGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| Pemigatinib (Pemazyre) | Approved | Small molecule | FGFR1/2/3 | Weak signal | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tinengotinib | Phase 3 | Small molecule | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition) | Weak signal | Featured results are safety only in this race | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(209 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Toripalimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (24)
November 2026 (1)
What to watch
December 2026 (23)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (82)
January 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (4)
What to watch
What to watch
What to watch
What to watch
April 2027 (2)
What to watch
What to watch
May 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (4)
What to watch
What to watch
What to watch
What to watch
December 2027 (31)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (64)
January 2028 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
April 2028 (4)
What to watch
What to watch
What to watch
What to watch
May 2028 (4)
What to watch
Company guidance: data expected 2H 2026 (Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.” Source ↗
What to watch
What to watch
What to watch
June 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (2)
August 2028 (4)
What to watch
What to watch
What to watch
What to watch
October 2028 (2)
November 2028 (3)
What to watch
What to watch
What to watch
December 2028 (20)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (26)
January 2029 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2029 (2)
April 2029 (2)
What to watch
What to watch
May 2029 (1)
What to watch
June 2029 (4)
What to watch
What to watch
What to watch
What to watch
July 2029 (1)
What to watch
August 2029 (1)
What to watch
September 2029 (3)
What to watch
What to watch
What to watch
October 2029 (1)
What to watch
November 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (8)
January 2030 (1)
What to watch
February 2030 (2)
June 2030 (1)
What to watch
July 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (2)
What to watch
What to watch
2031 (3)
March 2031 (1)
What to watch
August 2031 (1)
What to watch
September 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent